Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion type Assertion NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_head.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion wasGeneratedBy ECO_0000203 NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_provenance.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion wasDerivedFrom lhgdn-20090331 NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_provenance.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion SIO_000772 18381570 NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_provenance.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion evidence source_evidence_literature NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_provenance.
- NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_assertion description "[Thyroid cancers with BRAF mutation are preferentially sensitive to MEK inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP112209.RA1_h7yYXfTPDdppgbUVS3X1EonR2UKiUot9ZeFvqRVSA130_provenance.